US 11,918,642 B2
HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens
Tsafrir S. Leket-Mor, Tempe, AZ (US); Bertram Jacobs, Tempe, AZ (US); Lydia Meador, Tempe, AZ (US); and Karen Kibler, Scottsdale, AZ (US)
Assigned to Arizona Board of Regents on Behalf of Arizona State University, Scottsdale, AZ (US)
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Filed on Sep. 29, 2021, as Appl. No. 17/489,106.
Application 17/489,106 is a continuation of application No. 16/396,676, filed on Apr. 27, 2019, abandoned.
Claims priority of provisional application 62/663,391, filed on Apr. 27, 2018.
Prior Publication US 2022/0088178 A1, Mar. 24, 2022
Int. Cl. A61K 39/21 (2006.01); C07K 14/16 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/21 (2013.01) [A61K 2039/5258 (2013.01); A61K 2039/575 (2013.01); C07K 14/161 (2013.01); C07K 14/162 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16234 (2013.01)] 19 Claims
 
1. A method of generating an immune response in a mammalian subject against HIV comprising:
administering a vaccinia virus-like particle (VLP) to the mammalian subject, wherein the vaccinia VLP presents HIV Gag, a fragment of gp41, or both; and
administering a plant-produced HIV VLP to the mammalian subject, wherein the plant-produced HIV VLP presents HIV Gag and a fragment of gp41 and is isolated from plant tissue transformed with a dual replicon geminivirus-based plant expression vector comprising a T-DNA region that comprises:
a first nucleic acid sequence encoding Gag and a first promoter region upstream of the first nucleic acid sequence encoding Gag; and
a second nucleic acid sequence encoding a fragment of gp41 and a second promoter upstream of the second nucleic acid sequence encoding a fragment of gp41,
wherein the mammalian subject is administered the vaccinia VLP and the plant-produced HIV VLP in an amount sufficient to generate an HIV immune response in the mammalian subject.